ClinicalTrials.gg
Not yet recruitingNCT07833202Updated Sep 24, 2026

A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

A Phase 3 interventional study of Sosimerasib in combination with IN10018 and Tislelizumab + Carboplatin + Pemetrexed in NSCLC, sponsored by Shanghai Jeyou Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Shanghai Jeyou Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a randomized, positive controlled, open-Label and multicenter phase III study, to evaluate the efficacy and safety of Sosimerasib in combination with IN10018 versus anti-PD-1 monoclonal antibody in combination with carboplatin and pemetrexed as the first-line treatment for the locally advanced or metastatic non-squamous non-small cell lung cancer with KRAS G12C mutation.

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

Shanghai Jeyou Pharmaceutical Co., Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically documented Stage IIIB or IIIC NSCLC disease not amenable for surgical resection or definitive chemoradiation or Stage IV Non-squamous NSCLC disease.
  2. Has KRAS G12C mutation confirmed by central laboratory.
  3. according to 1.1.
  4. An Eastern Cooperative Group () performance status of 0 or 1.
  5. Adequate organ function.
  6. ≥3 months in the opinion of the Investigator
  7. Male and female participants of must agree to use effective during and for 6 months after treatment

Exclusion criteria

Exclusion Criteria:

  1. Has another known driver mutation with approved targeted therapy.
  2. Participants with carcinomatous meningitis or spinal cord compression; or with other evidence indicating that central nervous system (CNS) or are not yet controlled.
  3. Prior treatment with KRAS G12C inhibitors, FAK inhibitors, or pan-RAS inhibitors.
  4. History of prior in the past 3 years, with the exception of curatively treated malignancies.
  5. Gastrointestinal (GI) tract disease causing the inability to take oral medication or affect drug absorption.
  6. Has uncontrolled cardiovascular disease, active severe infection, interstitial lung disease, or disease.
  7. Any condition that, in the opinion of the Investigator, would interfere with participation or study results
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
416 participants (estimated)

Study arms

  • Experimental
    Study Arm

    Sosimerasib in combination with IN10018

    Drug: Sosimerasib in combination with IN10018

  • Active comparator
    Control Arm

    anti-PD-1 monoclonal antibody in combination with chemotherapy

    Drug: Tislelizumab + Carboplatin + Pemetrexed

Interventions

  • DrugSosimerasib in combination with IN10018

    Drug page: Ifebemtinib

    Participants receive Sosimerasib in combination with IN10018 orally once daily (QD) in a 21-day cycle, until disease progression or unacceptable toxicity

  • DrugTislelizumab + Carboplatin + Pemetrexed

    Drug pages: Tislelizumab · Carboplatin · Pemetrexed

    Participants receive Tislelizumab Q3W IV until disease progression or up to 2 years, plus Carboplatin Q3W IV for up to 4 cycles, plus Pemetrexed Q3W IV until disease progression.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Defined as time from randomization until disease progression or death from any cause, whichever occurs first assessed per RECIST v1.1 by blinded independent central review (BICR).

    Time frame: 30 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    Defined as complete response (PR) + partial response (PR) assessed per RECIST v1.1 by BICR

    Time frame: 30 months

  2. Overall Survival (OS)

    Defined as time from randomization to death by any cause

    Time frame: up to 60 months

  3. Disease Control Rate (DCR)

    Defined as ORR + stable disease (SD) assessed per RECIST v1.1 by BICR

    Time frame: 30 months

  4. Duration of Response (DoR)

    Defined as time from first evidence of PR or CR to disease progression or death due to any cause, whichever occurs first, assessed per RECIST v1.1 by BICR

    Time frame: 30 months

  5. PFS by investigator assessment

    Defined as time from randomization until disease progression or death from any cause, whichever occurs first assessed per RECIST v1.1 by investigator assessment.

    Time frame: up to 30 months

  6. Number of participants with adverse event

    Number of participants with treatment-related adverse events as assessed by CTCAE v6.0

    Time frame: 30 months

  7. Patient-reported outcome (PRO) questionnaire including EORTC QLQ-C30

    Reports of health status directly from participants

    Time frame: up to 30 months

  8. Patient-reported outcome (PRO) questionnaire including EORTC QLQ-LC13.

    Reports of health status directly from participants

    Time frame: up to 30 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Apr 2029, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2026
First posted
Sep 22, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2029
CompletionEst.
Sep 2030
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07833202
Responsible party
Sponsor
First posted
Sep 22, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Sep 2030 (estimated)
Last update
Sep 24, 2026

Study contacts

Jieting Zhao
Contact
zhaojieting@jeyoupharma.com
021-60198525

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifebemtinib

Start the discussion